GlassScriptPhysician profile
Jack M Shields
NPI 1730119934
$2,008.42
in general payments reported to CMS, 2019-2025
13 companies · $160 in 2025
The $160 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $621 · 2020: $327 · 2021: $170 · 2022: $201 · 2023: $316 · 2024: $214 · 2025: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $689.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $585.72 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $455.55 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $338.14 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $157.42 | 2019-2020 | |
| Amarin Pharma, INC. | $137.25 | 2019 | |
| Lilly USA, LLC | $115.30 | 2023-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.70 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $40.06 | 2019 | |
| Amgen INC. | $29.07 | 2024-2025 | Krystexxa |
| Janssen Pharmaceuticals, INC | $17.04 | 2020 | |
| Sanofi-Aventis U.S. LLC | $14.19 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.52 | 2019 | |
| Abbott Laboratories | $13.46 | 2024 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Shields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.